BioHarvest Sciences Guides Q4 2025 Revenue at $9–$9.5 Million with Adjusted EBITDA Near Breakeven

Reuters11-01

BioHarvest Sciences Guides Q4 2025 Revenue at $9-$9.5 Million with Adjusted EBITDA Near Breakeven

BioHarvest Sciences Inc. has released its preliminary unaudited financial guidance for the third and fourth quarters of 2025. For the third quarter, the company expects revenue of approximately $9.1 million, in line with management's previous guidance, and an adjusted EBITDA in the range of negative $0.7 million to negative $0.4 million. Cash and cash equivalents as of September 30, 2025, totaled around $11 million. For the fourth quarter, BioHarvest projects revenue between $9 million and $9.5 million, with adjusted EBITDA anticipated to range from negative $0.6 million to breakeven. The company notes growth in its VINIA® business and CDMO Services, supported by new product launches and marketing initiatives set to roll out in the fourth quarter. Management indicates that BioHarvest is well positioned to reach adjusted EBITDA breakeven in the near term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000011), on October 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580449449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-01 00:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580449449","market":"nz","top_or_hot":-1,"title":"BioHarvest Sciences Guides Q4 2025 Revenue at $9–$9.5 Million with Adjusted EBITDA Near Breakeven","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioHarvest Sciences Guides Q4 2025 Revenue at $9-$9.5 Million with Adjusted EBITDA Near Breakeven\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioHarvest Sciences Inc. has released its preliminary unaudited financial guidance for the third and fourth quarters of 2025. For the third quarter, the company expects revenue of approximately $9.1 million, in line with management's previous guidance, and an adjusted EBITDA in the range of negative $0.7 million to negative $0.4 million. Cash and cash equivalents as of September 30, 2025, totaled around $11 million. For the fourth quarter, BioHarvest projects revenue between $9 million and $9.5 million, with adjusted EBITDA anticipated to range from negative $0.6 million to breakeven. The company notes growth in its VINIA® business and CDMO Services, supported by new product launches and marketing initiatives set to roll out in the fourth quarter. Management indicates that BioHarvest is well positioned to reach adjusted EBITDA breakeven in the near term.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BHST\">Bioharvest Sciences</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000011), on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioHarvest Sciences Guides Q4 2025 Revenue at $9–$9.5 Million with Adjusted EBITDA Near Breakeven</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioHarvest Sciences Guides Q4 2025 Revenue at $9–$9.5 Million with Adjusted EBITDA Near Breakeven\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-01 00:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioHarvest Sciences Guides Q4 2025 Revenue at $9-$9.5 Million with Adjusted EBITDA Near Breakeven\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioHarvest Sciences Inc. has released its preliminary unaudited financial guidance for the third and fourth quarters of 2025. For the third quarter, the company expects revenue of approximately $9.1 million, in line with management's previous guidance, and an adjusted EBITDA in the range of negative $0.7 million to negative $0.4 million. Cash and cash equivalents as of September 30, 2025, totaled around $11 million. For the fourth quarter, BioHarvest projects revenue between $9 million and $9.5 million, with adjusted EBITDA anticipated to range from negative $0.6 million to breakeven. The company notes growth in its VINIA® business and CDMO Services, supported by new product launches and marketing initiatives set to roll out in the fourth quarter. Management indicates that BioHarvest is well positioned to reach adjusted EBITDA breakeven in the near term.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BHST\">Bioharvest Sciences</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000011), on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHST","symbol_name":"BIOHARVEST SCIENCES INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL5scG5W:1","article_id":"2580449449","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580449449","pubTimestamp":1761929932,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioHarvest Sciences Inc. has released its preliminary unaudited financial guidance for the third and fourth quarters of 2025. For the third quarter, the company expects revenue of approximately $9.1 million, in line with management's previous guidance, and an adjusted EBITDA in the range of negative $0.7 million to negative $0.4 million. Cash and cash equivalents as of September 30, 2025, totaled around $11 million. For the fourth quarter, BioHarvest projects revenue between $9 million and $9.5 million, with adjusted EBITDA anticipated to range from negative $0.6 million to breakeven. The company notes growth in its VINIA business and CDMO Services, supported by new product launches and marketing initiatives set to roll out in the fourth quarter. Management indicates that BioHarvest is well positioned to reach adjusted EBITDA breakeven in the near term.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BHST":"BIOHARVEST SCIENCES INC","BK4183":"个人用品"},"translate_title":"BioHarvest Sciences预计2025年第四季度收入为9-950万美元，调整后EBITDA接近盈亏平衡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHST":0.9},"content_text":"BioHarvest Sciences Guides Q4 2025 Revenue at $9-$9.5 Million with Adjusted EBITDA Near Breakeven\n    \n\n        BioHarvest Sciences Inc. has released its preliminary unaudited financial guidance for the third and fourth quarters of 2025. For the third quarter, the company expects revenue of approximately $9.1 million, in line with management's previous guidance, and an adjusted EBITDA in the range of negative $0.7 million to negative $0.4 million. Cash and cash equivalents as of September 30, 2025, totaled around $11 million. For the fourth quarter, BioHarvest projects revenue between $9 million and $9.5 million, with adjusted EBITDA anticipated to range from negative $0.6 million to breakeven. The company notes growth in its VINIA® business and CDMO Services, supported by new product launches and marketing initiatives set to roll out in the fourth quarter. Management indicates that BioHarvest is well positioned to reach adjusted EBITDA breakeven in the near term.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioharvest Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001723464-25-000011), on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580449449","isCrawlerRequest":true}